Hepatitis
News
HCV regimen found safe, effective in patients with severe renal disease
A 12-week regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir achieved sustained viral response for 90% of patients with genotype 1...
News
Chronic HCV boosts hospitalization risk, not just for liver
Patients with chronic hepatitis C infection have significantly greater risk of hospitalization for a range of health issues.
News
Hepatitis A and B combo vaccinations remain effective after 15 years
Young adults who received a combined hepatitis A and B vaccination at age 12-15 years maintained immunity after 15 years, making a booster shot...
News
Hepatitis B vaccine in infancy provides long-term protection into adolescence
Pediatric doses of hepatitis B vaccine can provide long-term protection against hepatitis B up to 15-16 years.
News
Initiative dramatically raises HCV screening, treatment
A hepatitis C awareness initiative dramatically raised the rate of HCV screening and treatment in a large American Indian population – the ethnic...
News
FDA publishes draft guidance for developing HCV antivirals
The U.S. Food and Drug Administration has issued revised draft guidance intended to foster the development of direct-acting antiviral drugs to...
News
Hepatitis Outlook: April 2016
Quantitative maternal surface antigen predicts hepatitis B virus infection in infants as well as maternal viral load does. Read about this and...
News
Hepatitis B vaccine immunogenic, safe in diabetes patients
The hepatitis B vaccine was immunogenic in adults with type 2 diabetes, had a safety profile similar to that of control subjects, and should be...
Conference Coverage
DAAs, HCV-positive livers could reduce transplant waiting list
Key clinical point: Using direct-acting antiviral (DAA) therapy and HCV-positive livers could help reduce the strain on liver transplant lists....
News
Hepatitis B test identifies active carriers
Key clinical point: The data confirm the predictability of a one-time test for chronic hepatitis B progression that combines hepatitis B surface...
Conference Coverage
Investigational HBV core inhibitor shows early clinical promise
An investigational drug that targets the hepatitis B virus (HBV) core protein is a “totally new approach” to treating chronic HBV infection...